Obseva SA, of Plan-les-Ouates, Switzerland, completed a phase I single and multiple ascending-dose study of OBE022, its once-daily, oral and selective prostaglandin F2alpha, or PGF2alpha, receptor antagonist candidate for the treatment of preterm labor in weeks 24 to 34 of pregnancy.